| No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES *
[Number of genes] |
KEGG PATHWAY
[Number of pathways] |
Disease ID *
[Number of diseases] |
| 1 |
Palovarotene |
Palovarotene |
D09365 |
- |
- |
[1] 272 |
| 2 |
Palovarotene dose level 1 |
Palovarotene |
D09365 |
- |
- |
[1] 272 |
| 3 |
Palovarotene dose level 2 |
Palovarotene |
D09365 |
- |
- |
[1] 272 |
| 4 |
Palovarotene dose level 3 |
Palovarotene |
D09365 |
- |
- |
[1] 272 |
| 5 |
Palovarotene dose level 4 |
Palovarotene |
D09365 |
- |
- |
[1] 272 |
| 6 |
Perhexiline |
Perhexiline |
D05442, D08340 |
[8] CACNA1C, CACNA1D, CACNA1F, CACNA1S, CPT1A, CPT1B, CPT1C, CPT2 |
[42] AMPK signaling pathway, Adipocytokine signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, Fatty acid degradation, Fatty acid metabolism, GABAergic synapse, Glucagon signaling pathway, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, PPAR signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Thermogenesis, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[2] 58, 272 |
| 7 |
Regn2477 |
- |
- |
- |
- |
[1] 272 |